Prof. Hui Li, Ph.D.
Deputy Director of Tianjin Cancer Institute

Director and Professor,Department of Gastrointestinal Cancer Biology

Education

1992.09~1996.07   Bachelor in Biochemistry , Naikai University

1999.09~2002.07   Master in Immunology, Tianjin Medical University

2002.09~2005.07   Ph.D in Oncology, Tianjin Medical University


Professional Experiences

1996.11~2002.11 Research Assistant, Tianjin Cancer Institute, Tianjin Medical University Cancer Institute & Hospital

2002.11~2007.11 Research Associate, Tianjin Cancer Institute, Tianjin Medical University Cancer Institute & Hospital

2006.06~2006.12  Visiting Scholar, University of California, Irvine

2007.12~2012.11  Associate Professor, Tianjin Cancer Institute, Tianjin Medical University Cancer Institute & Hospital

2008.02~2008.10  Visiting Scholar, Weill Cornell Medical College

2012.11~ present  Professor, Tianjin Cancer Institute, Tianjin Medical University Cancer Institute & Hospital


Research Focus

Prof. Li received Ph.D. degree from the Tianjin Medical University, did postgraduate training at Weill Cornell Medical College in US. She has dedicated to cancer immunology research for several years.  In the last decade, Prof. Li focused on the characters and mechanisms of cancer immune microenvironment, which included regulatory T cells (Tregs), tumor associated macrophage (TAMs), etc. Her team made full use of the patient resources of our hospital and condensed scientific problems from clinical practice. Prof. Li proposed to subdivide the Tregs with or without TNFR2 expression and introduced the EGFR signaling pathway into the regulation of M2-type macrophage polarization. 


She also participated into the projects about the development of approaches of cancer immunotherapy based on dendritic cells or CTLs. The study of immune microenvironment and its regulatory network provides theoretical basis for elucidation of the development mechanism of gastric cancer and the formulation of relevant therapeutic strategies. In recent years, she has taken charge of 4 projects granted by National Science Foundation of China. She has been awarded Tianjin Technology Progress Prize. More than 50 papers have been published.


Selected Publications

1. Zhao H, Wang Y, Yu J, Wei F, Cao S, Zhang X, Dong N, Li H, Ren X. Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial. Clin Colorectal Cancer, 15(3):228-235, 2016. PMID: 27052743.https://www.sciencedirect.com/science/article/pii/S1533002816300172?via%3Dihub

2. Sun L, Jin H, Li H. GARP: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasing. Oncotarget, 7(27):42826-42836, 2016. PMID: 27095576.http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=8753&path[]=26343

3. Wang Y, Zhao H, Gao X, Wei F, Ren X. Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma. Oncotarget, 7(18):26070-26086, 2014. PMID: 27036025.http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=8429&path[]=25025

4. Gao X, Wang Y, Zhao H, Wei F, Ren X. Plasma miR-324-3p and miR-1285 as diagnostic and prognostic biomarkers for early stage lung squamous cell carcinoma. Oncotarget, 7(37):59664-59675, 2014. PMID: 27517633. http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=11198&path[]=35452

5. Gao X, Wu Y, Yu W, Li H. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma. Oncotarget, 7(49):81670, 2016. PMID: 27835574.http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13164&path[]=50039

6. Jin H, Sun L, Tang L, Yu W, Li H. Expression of GARP is increased in tumor-infiltrating regulatory T cells and is correlated to clinicopathology of lung cancer patients. Frontiers in Immunology, 8, 138, 2017. PMID: 28261204.https://www.frontiersin.org/articles/10.3389/fimmu.2017.00138/full

7. Qu Y, Zhao G, Li H. Forward and Reverse Signaling Mediated by Transmembrane Tumor Necrosis Factor-Alpha and TNF Receptor 2: Potential Roles in an Immunosuppressive Tumor Microenvironment. Frontiers in Immunology, 8:1675, 2017. PMID: 29234328.https://www.frontiersin.org/articles/10.3389/fimmu.2017.01675/full

8. Yang L, Du C, Wu L, Yu J, An X, Yu W, Cao S, Li H, Ren X. Cytokine-induced killer cells modulates resistance to cisplatin in the A549/DDP cell line. Journal of Cancer, 8(16):3287, 2017. PMID: 29158802.http://www.jcancer.org/v08p3287.htm

9. Jia L, Yan F, Cao W, Chen Z, Zheng H, Li H. Dysregulation of cul4a and cul4b ubiquitin ligases in lung cancer. Journal of Biological Chemistry, 292(7):2966-2978, 2017. PMID: 27974468.http://www.jbc.org/content/292/7/2966

10. Li T, Gao X, Han L, Yu J, Li H. Identification of hub genes with prognostic values in gastric cancer by bioinformatics analysis. World Journal of Surgical Oncology, 16(1):114, 2018. PMID: 29921304.https://wjso.biomedcentral.com/articles/10.1186/s12957-018-1409-3